<DOC>
	<DOCNO>NCT01185184</DOCNO>
	<brief_summary>This study explore drug behavior safety follow single dose two 20 milligram CP-690,550 osmotic capsule 12 healthy volunteer . These compare 10 milligram immediate release tablet , use 3 way crossover design .</brief_summary>
	<brief_title>Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male and/or female subject Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . Clinically significant infection within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>21 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>control release</keyword>
	<keyword>Phase 1</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
</DOC>